| A neutrophil activation signature predicts critical illness and mortality in COVID-19 ML Meizlish, AB Pine, JD Bishai, G Goshua, ER Nadelmann, M Simonov, ... Blood advances 5 (5), 1164-1177, 2021 | 287 | 2021 |
| Circulating markers of angiogenesis and endotheliopathy in COVID-19 AB Pine, ML Meizlish, G Goshua, CH Chang, H Zhang, J Bishai, P Bahel, ... Pulmonary Circulation 10 (4), 2045894020966547, 2020 | 138 | 2020 |
| m6A modification prevents formation of endogenous double-stranded RNAs and deleterious innate immune responses during hematopoietic development Y Gao, R Vasic, Y Song, R Teng, C Liu, R Gbyli, G Biancon, R Nelakanti, ... Immunity 52 (6), 1007-1021. e8, 2020 | 121 | 2020 |
| A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies Y Song, A Rongvaux, A Taylor, T Jiang, T Tebaldi, K Balasubramanian, ... Nature communications 10 (1), 366, 2019 | 78 | 2019 |
| Achieving totally local anticoagulation on blood contacting devices R Gbyli, A Mercaldi, H Sundaram, KA Amoako Advanced Materials Interfaces 5 (4), 1700954, 2018 | 42 | 2018 |
| Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies G Biancon, P Joshi, JT Zimmer, T Hunck, Y Gao, MD Lessard, ... Molecular cell 82 (6), 1107-1122. e7, 2022 | 28 | 2022 |
| Combined liver–cytokine humanization comes to the rescue of circulating human red blood cells Y Song, L Shan, R Gbyli, W Liu, T Strowig, A Patel, X Fu, X Wang, ML Xu, ... Science 371 (6533), 1019-1025, 2021 | 23 | 2021 |
| Humanized mice as preclinical models for myeloid malignancies R Gbyli, Y Song, S Halene Biochemical Pharmacology 174, 113794, 2020 | 15 | 2020 |
| In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2 R Gbyli, Y Song, W Liu, Y Gao, G Biancon, NS Chandhok, X Wang, X Fu, ... Leukemia 36 (5), 1313-1323, 2022 | 11 | 2022 |
| Improving the hemocompatibility of biomedical polymers K Amoako, R Gbyli Hemocompatibility of biomaterials for clinical applications, 223-252, 2018 | 11 | 2018 |
| ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability control Y Gao, JT Zimmer, R Vasic, C Liu, R Gbyli, SJ Zheng, A Patel, W Liu, Z Qi, ... Cell Reports 42 (10), 2023 | 3 | 2023 |
| Multi-omics profiling of U2AF1 mutants dissects pathogenic mechanisms affecting RNA granules in myeloid malignancies G Biancon, P Joshi, JT Zimmer, T Hunck, Y Gao, MD Lessard, ... bioRxiv, 2021.04. 22.441020, 2021 | 3 | 2021 |
| Functional analysis of human hematopoietic stem cells in vivo in humanized mice Y Song, R Gbyli, X Fu, S Halene Cell Reprogramming for Immunotherapy: Methods and Protocols, 273-289, 2020 | 3 | 2020 |
| PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors R Gbyli, Y Song, W Liu, Y Gao, NS Chandhok, X Fu, X Wang, A Patel, ... Blood 134, 4222, 2019 | 3 | 2019 |
| Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes MA Fischer, Y Song, MP Arrate, R Gbyli, MT Villaume, BN Smith, ... Haematologica 108 (2), 522, 2023 | 2 | 2023 |
| MCL1 dependence across MDS subtypes and dual inhibition of MCL1 and BCL2 in MISTRG6 mice MA Fischer, Y Song, R Gbyli, MP Arrate, MT Villaume, MA Childress, ... bioRxiv, 2020.06. 05.133090, 2020 | 2 | 2020 |
| In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice Y Song, L Shan, R Gbyli, W Liu, X Fu, X Wang, A Qin, A Patel, Y Gao, ... Blood 134, 338, 2019 | 2 | 2019 |
| Variable response to BCL2 inhibition in MDS is enhanced across MDS subtypes with synergistic combination of BCL2+ MCL1 inhibition MA Fischer, M Arrate, MA Childress, BN Smith, Y Song, R Gbyli, T Stricker, ... Blood 134, 2982, 2019 | 1 | 2019 |
| 3064–ALKBH5 MODULATES HEMATOPOIETIC STEM AND PROGENITOR CELL ENERGY METABOLISM THROUGH M6A MODIFICATION-MEDIATED RNA STABILITY CONTROL Y Gao, G Biancon, R Flavell, R Gbyli, S Halene, R Kibbey, HB Li, Y Li, ... Experimental Hematology 124, S82, 2023 | | 2023 |
| Abstract B016: A novel epigenetic factor is required for the acquisition of TKI resistance in lung adenocarcinoma via the regulation of oncogene amplicons RM Starble, EG Sun, TB Jensen, R Gbyli, N Sun, AZ Xiao Cancer Research 82 (23_Supplement_2), B016-B016, 2022 | | 2022 |
